<SEC-DOCUMENT>0001580642-25-003116.txt : 20250514
<SEC-HEADER>0001580642-25-003116.hdr.sgml : 20250514
<ACCEPTANCE-DATETIME>20250514155152
ACCESSION NUMBER:		0001580642-25-003116
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250514
DATE AS OF CHANGE:		20250514

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Zentalis Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001725160
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				823607803
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-91478
		FILM NUMBER:		25944993

	BUSINESS ADDRESS:	
		STREET 1:		10275 SCIENCE CENTER DRIVE
		STREET 2:		SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(858) 263-4333

	MAIL ADDRESS:	
		STREET 1:		10275 SCIENCE CENTER DRIVE
		STREET 2:		SUITE 200
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Zentalis Pharmaceuticals, LLC
		DATE OF NAME CHANGE:	20200107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Zeno Pharma, LLC
		DATE OF NAME CHANGE:	20171212

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EVENTIDE ASSET MANAGEMENT, LLC
		CENTRAL INDEX KEY:			0001442891
		ORGANIZATION NAME:           	
		EIN:				262508416
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G/A

	BUSINESS ADDRESS:	
		STREET 1:		ONE INTERNATIONAL PLACE
		STREET 2:		SUITE 4210
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110
		BUSINESS PHONE:		877-771-3836

	MAIL ADDRESS:	
		STREET 1:		ONE INTERNATIONAL PLACE
		STREET 2:		SUITE 4210
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02110

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EVENTIDE ASSET MANAGMENT LLC
		DATE OF NAME CHANGE:	20080813
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: EVENTIDE ASSET MANAGEMENT, LLC -->
          <cik>0001442891</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>4</amendmentNo>
      <securitiesClassTitle>Common Stock, $0.001 par value per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>03/31/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001725160</issuerCik>
        <issuerName>Zentalis Pharmaceuticals, Inc.</issuerName>
        <issuerCusip>98943L107</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>10275 Science Center Drive</com:street1>
          <com:street2>Suite 200</com:street2>
          <com:city>San Diego</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>92121</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(b)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Eventide Asset Management, LLC</reportingPersonName>
      <citizenshipOrOrganization>DE</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>0.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>0</classPercent>
      <typeOfReportingPerson>IA</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Finny Kuruvilla, M.D. Ph. D.</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>0.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>0</classPercent>
      <typeOfReportingPerson>HC</typeOfReportingPerson>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <coverPageHeaderReportingPersonDetails>

      <reportingPersonName>Robin C. John</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>0.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>0</classPercent>
      <typeOfReportingPerson>HC</typeOfReportingPerson>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>Zentalis Pharmaceuticals, Inc.</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>10275 Science Center Drive, Suite 200, San Diego, CA, 92121</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>(i)    Eventide Asset Management, LLC ("Eventide")
(ii)   Finny Kuruvilla, M.D., Ph.D. ("Kuruvilla")
(iii)  Robin C. John ("John")</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>Eventide, Kuruvilla and John:
One International Place, Suite 4210
Boston, Massachusetts 02110</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Eventide:  Delaware
Kuruvilla:  United States
John:  United States</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>N</notApplicableFlag>
        <typeOfPersonFiling>IA</typeOfPersonFiling>
        <typeOfPersonFiling>HC</typeOfPersonFiling>
      </item3>
      <item4>
        <amountBeneficiallyOwned>(i)     Eventide: 0
(ii)    Kuruvilla: 0
(iii)   John:       0</amountBeneficiallyOwned>
        <classPercent>(i)     Eventide:     0%
(ii)    Kuruvilla:     0%
(iii)   John:           0%</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>(1)   Eventide:     0
(2)   Kuruvilla:     0
(3)   John:           0</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>(1)   Eventide: 0
(2)   Kuruvilla: 0
(3)   John: 0</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>(1)   Eventide:     0
(2)   Kuruvilla:     0
(3)   John:           0</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>(1)   Eventide: 0
(2)   Kuruvilla: 0
(3)   John: 0</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>N</notApplicableFlag>
        <classOwnership5PercentOrLess>Y</classOwnership5PercentOrLess>
      </item5>
      <item6>
        <notApplicableFlag>Y</notApplicableFlag>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <exhibitInfo>EXHIBIT 1

WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons  are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in writing that such Statement or amendments thereto is filed on behalf of each of them;

NOW, THEREFORE, the parties hereto agree as follows:

Eventide Asset Management, LLC, Finny Kuruvilla, M.D., Ph. D. and Robin C. John do hereby agree, in accordance with Rule 13d-1(k)(1) under the Act, to file a Statement on Schedule 13G relating to their ownership of the Common Stock of the Issuer, and do hereby further agree that said Statement on Schedule 13G shall be filed on behalf of each of them.


Eventide Asset Management, LLC

Date:  May 14, 2025
By: /s/  Peter J. Luiso
Name:  Peter J. Luiso
Title:    General Counsel

Date:  May 14, 2025
Finny Kuruvilla, M.D., Ph. D.
By: /s/  Finny Kuruvilla, M.D., Ph. D.
Name:  Finny Kuruvilla, M.D., Ph. D.

Date:  May 14, 2025
Robin C. John
By: /s/  Robin C. John
Name:  Robin C. John</exhibitInfo>
    <signatureInformation>
      <reportingPersonName>Eventide Asset Management, LLC</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Peter J. Luiso</signature>
        <title>Peter J. Luiso, General Counsel</title>
        <date>05/14/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Finny Kuruvilla, M.D. Ph. D.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Finny Kuruvilla, M.D., Ph. D.</signature>
        <title>Finny Kuruvilla, M.D., Ph. D.</title>
        <date>05/14/2025</date>
      </signatureDetails>
    </signatureInformation>
    <signatureInformation>
      <reportingPersonName>Robin C. John</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Robin C. John</signature>
        <title>Robin C. John</title>
        <date>05/14/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
